Innovating the Future of Cancer and Autoimmune Therapies.
At Trethera, we are advancing innovative therapies across oncology and autoimmune diseases. Our robust pipeline reflects our commitment to addressing unmet medical needs and improving patient outcomes.
TRE-515 is an orally taken pill under development for autoimmune diseases and in clinical trials for solid tumors. As a first-in-class drug, TRE-515 blocks a key enzyme called deoxycytidine kinase (dCK) that has been implicated in abnormal cell proliferation.
By achieving even one success in our pipeline we create a waterfall effect for additional therapies.
Broad Uses
TRE-515 is a first-in-class therapy aimed at treating ADEM, optic neuritis, MS, cancer, lupus, Crohn’s disease and more —a unique, diversified opportunity within a single drug.
More Shots on Goal
Each clinical trial we conduct opens new doors for success, with each disease indication creating multiple pathways to impact and changing patient lives.